ESMO Congress 2022
![Matteo Lambertini](/var/esmo/storage/images/media/esmo-daily-reporter/images/portraits/matteo-lambertini/11859220-1-eng-GB/matteo-lambertini_i770.jpg)
The effect of ‘publish or perish’ on young academic oncologists
Oncologists at an early stage in their career may fall into the trap of predatory journals whilst seeking to publish their research
![Practice-changing treatments in GU cancers continue to evolve](/var/esmo/storage/images/esmo-daily-reporter/esmo-congress-2022/esmo-awards-2022/practice-changing-treatments-in-gu-cancers-continue-to-evolve/11885273-2-eng-GB/practice-changing-treatments-in-gu-cancers-continue-to-evolve_i770.jpg)
Practice-changing treatments in GU cancers continue to evolve
Finding the best treatment strategy for patient subpopulations and adequate funding are key to further advancing the field, says ESMO Award 2022 recipient Prof. Karim Fizazi
![AI and machine learning may change the course of translational research](/var/esmo/storage/images/esmo-daily-reporter/esmo-congress-2022/esmo-awards-2022/ai-and-machine-learning-may-change-the-course-of-translational-research/11861395-2-eng-GB/ai-and-machine-learning-may-change-the-course-of-translational-research_i770.jpg)
AI and machine learning may change the course of translational research
However, according to the winner of the ESMO Award for Translational Research 2022, Dr Samra Turajlic, results will only be achieved through a collaborative effort of the oncology community
![More women in leadership roles are key to patient-centred medicine](/var/esmo/storage/images/esmo-daily-reporter/esmo-congress-2022/esmo-awards-2022/more-women-in-leadership-roles-are-key-to-patient-centred-medicine/11859628-2-eng-GB/more-women-in-leadership-roles-are-key-to-patient-centred-medicine_i770.jpg)
More women in leadership roles are key to patient-centred medicine
According to this year’s ESMO Women for Oncology awardee Prof. Fatima Cardoso, steps forward in gender equality have been made, but progress is still slow
![More needs to be done in renal cancer](/var/esmo/storage/images/esmo-daily-reporter/esmo-congress-2022/esmo-awards-2022/more-needs-to-be-done-in-renal-cancer/11861215-2-eng-GB/more-needs-to-be-done-in-renal-cancer_i770.jpg)
More needs to be done in renal cancer
Up to 90% of patients will die from metastatic disease and the search for biomarkers lags behind other tumour types, says ESMO Lifetime Achievement Award 2022 winner Prof. Bernard Escudier
![Winette van der Graaf](/var/esmo/storage/images/media/esmo-daily-reporter/images/portraits/winette-van-der-graaf/11921342-1-eng-GB/winette-van-der-graaf_i770.jpg)
Enhanced patient participation in trials may help make cancer research more heterogeneous
In the Patient Advocacy Track, the importance and challenges around placing the patient at the centre of clinical trials